Introduction: Calcium (Ca²⁺) homeostasis dysregulation has been linked to many age-related diseases such as Alzheimer's, Parkinsons disease, Huntington's disease and many more. SOCE is one of the major pathways involved in the regulation of Ca²⁺ homeostasis intracellularly. Human derived fibroblasts (HDFs) have limited replicative capacity known as the Hayflick limit after which cells undergo growth arrest known as replicative senescence. Aims. To study the activity of SOCE in cellular ageing and the effect of pharmacological modulation of SOCE on cellular senescence.

Methods: The activity of SOCE in young and aged HDFs was assessed in calcium influx assays using Fluo-4 calcium indicator. To understand the effect of SOCE modulation on cellular senescence, HDFs were treated with DMSO control or SOCE agonist, IA65 (1, 3 and 10 µM), or SOCE inhibitor, Synta-66 (1 and 10 µM) and cells were passaged at fixed time interval of four and three days. Cumulative population doublings (CPD) were calculated at each passage until the cells reached the plateau phase of cell growth (Passage 38).

Results: Calcium influx assays demonstrated that SOCE pathway is active in the HDFs and can be regulated by its pharmacological modulators, IA65 and Synta-66. In addition, HDFs treated with IA65 at 3 µM concentration showed a delayed plateauing of the CPD curve compared to the other treatment groups.

Discussion: SOCE is present in HDF and can be modulated using IA65 and Synta-66. Preliminary data shows that there is a modest effect of SOCE activator, IA65 at 3 µM, on delaying the onset of replication arrest, however further investigation is needed to confirm the effect of the drug on delaying cellular senescence. Given the implication of cellular senescence in various pathological conditions, identification of novel therapeutic targets against cellular senescence, may pave the way to treatment of these conditions.